NICE rebuffs Revolade for ITP

The U.K.'s NICE issued a final appraisal determination recommending against the use of Revolade eltrombopag from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) in its approved indications -- to treat chronic idiopathic thrombocytopenic purpura (ITP) in splenectomized patients who are refractory to other treatments and as a second-line treatment of non-splenectomized patients for whom surgery is contraindicated. The decision is in line with a June preliminary appraisal. ...